Penumbra (PEN) Completes STORM-PE Trial Enrollment

Penumbra, Inc. (PEN) completes enrollment in STORM-PE clinical trial, evaluating computer assisted vacuum thrombectomy for treating acute intermediate-high risk pulmonary embolism. With 900,000 annual PE cases in the US, Penumbra’s Lightning Flash portfolio aims to address venous and pulmonary thrombus, leading to improved gross profits and growth guidance.

Baron Funds initiates a position in Penumbra, Inc. (PEN), recognizing its leading medical devices for treating conditions like PE, DVT, ischemic stroke, and more. Penumbra’s mechanical thrombectomy devices use advanced technology to maximize clot removal speed while minimizing blood loss, positioning the company for continued success and growth in the healthcare industry.

Read more at Yahoo Finance: Penumbra (PEN) Announces Completion of Enrollment in STORM-PE Clinical Trial